GF
ROSG

Gerstein Fisher’s Rosetta Genomics Ltd. ROSG Stock Holding History

Gerstein Fisher’s Portfolio ROSG Stock Details ROSG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-917
Closed -$27K – 435
2015
Q3 		$27K Buy
+917
New +$31.3K ﹤0.01% 400

Other funds holding ROSG

HCM
Highlander Capital Management Short Hills, New Jersey $292M AUM 22.24% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
ICAS
Investors Capital Advisory Services Lynnfield, Massachusetts $521M AUM 1.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Gerstein Fisher's ROSG Position: Q4 2015 in Review

Gerstein Fisher sold out of Rosetta Genomics Ltd. (ROSG) in Q4 2015, closing a stake of 917 shares — an estimated $27K sold.

Gerstein Fisher first reported a position in ROSG in Q3 2015 and held it in 1 quarter. The position peaked at $27K in Q3 2015. 11 funds tracked by Wall St. Rank hold ROSG as of Q4 2015.

  • Gerstein Fisher reported no remaining Rosetta Genomics Ltd. position as of Q4 2015 after selling out during the quarter.
  • Gerstein Fisher sold 917 Rosetta Genomics Ltd. shares in Q4 2015, an estimated $27K.
  • Gerstein Fisher first reported a position in Rosetta Genomics Ltd. in Q3 2015 and held it in 1 quarter.
  • Gerstein Fisher's Rosetta Genomics Ltd. position peaked at $27K in Q3 2015.
  • 11 funds tracked by Wall St. Rank held Rosetta Genomics Ltd. as of Q4 2015.

Based on Gerstein Fisher's 13F filing for Q4 2015, filed 11 Feb 2016.